Pharmaceutical

Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments

The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with fibrostenosing Crohn’s disease.

Oct 26, 2024 - 04:00
Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with fibrostenosing Crohn’s disease.
Read the original article

Tags:

Previous Article

Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline

Next Article

Dyno and Roche collaborate on neurological gene therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: When it comes to policing pharma, the FTC says it’s on ‘an incredible winning streak’

STAT+: When it comes to policing pharma, the FTC says i...

Jan 24, 2024

When confronted with mysterious illness in college, ‘Chronically Catherine’ started writing

When confronted with mysterious illness in college, ‘Ch...

Apr 5, 2023

Intercept suffers setback with negative AdCom decision for NASH therapy

Intercept suffers setback with negative AdCom decision ...

May 22, 2023